http://rdf.ncbi.nlm.nih.gov/pubchem/patent/IE-43956-B1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3a5173a7d063a9f70ca7b5e86fc23863 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D213-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D213-38 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D213-64 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D213-82 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D213-85 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D213-80 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D213-74 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D213-75 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D213-73 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D213-53 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D213-73 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D213-74 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D213-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D213-38 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D213-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D213-64 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D213-75 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D213-82 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D213-80 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D213-85 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-44 |
| filingDate | 1976-10-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 1981-07-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | IE-43956-B1 |
| titleOfInvention | Pyridinyl-2n1h)-pyridinones and preparation |
| abstract | 1512129 3,21 - ,3,31 - and 3,41 - bipyridin - 6- (1H)-ones STERLING DRUG Inc 28 Sept 1976 [14 Oct 1975 21 July 1976] 40246/76 Heading C2C The compounds comprises compounds of formula and their acid addition salts, wherein PY is pyridyl (possibly R0 1-2 substituted, where R‹ is C 1-6 alkyl), R is H, R‹ or C 2-6 hydroxyalkyl, and Q is NO 2 , CN, H, CONH 2 , halogen, NH 2 , NHR‹, NR0 2 , C 1-6 alkanoylamino, NHCOOR0 or NHCH : C(COOR0) 2 . In examples, these compounds are prepared by reacting cyanoacetamide either with a substituted acrolein Me 2 NCH : C(PY(CHO, or with PYCH(CHO) 2 to give the nitriles (Q=CN), hydrolysing the latter to give the amides (Q = CONH 2 ) (alternatively made by an anlogous cyclization) or the acids (I : Q = CO 2 H) (IA) and decarboxylating the latter to the 3-unsubstituted compounds (IB) (Q = H), which may be reacted with halogen to give (IC) (Q=halogen). (IA) or (IB) can be reacted with nitric/sulphuric acids to give the nitro compounds (ID) (Q=NO 2 ) which are optionally N-alkylated to give (IE) (Q=NO 2 , R#H) (in the latter reaction a by-product such as 6-ethoxy-5-nitro-3,41-bipyridine may be formed). (ID) and (IE) are reduced to give the amines (I#) (Q=NA 2 ), which are also formed by Hofmann reaction of the amides. (IF) may be directly di-N-methylated [whereas the products generally in which Q=NHR0 or NR0 2 are obtained by reacting (IC) with R0NH 2 or R0 2 NH], alkanoylated, reacted with R‹OCH: C(CO 2 R0) 2 or with 1,11-carbonyldiimidazole, 2 in this case giving the intermediates (I : Q = imidazol - 1 - ylcarbonyl) which are reacted with R0OH to give the carbamates (Q = NHCOOR0). Therapeutic compositions having cardiotonic (and where Q=H, bronchodilates) activity comprise compounds of the above formula (excepting those where Q=NO 2 , CONH 2 or halogen), and may be administered orally or parenterally. |
| priorityDate | 1975-10-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 277.